OakChart

Nexalin Technology Inc

NXLHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 10:59 AM ET

1.53+0.06 (4.08%)
2026-11-11 17:02 CET
Market cap
1.69 USD m
Revenue, TTM
0.22 USD m
Net income, TTM
-8.99 USD m
Free cash flow, TTM
-6.18 USD m
EPS diluted, TTM
-14.02
P/E
-
Compare

Price

NXL against its 20, 50 and 200-day averages
2050200beatmiss
0.0010.0020.0031.2M62.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NXLclose 1.5320-day 1.7750-day 3.51200-day 10.201.53

96.2% under the 52-week high of 40.20 on 11 Nov 2025. 52-week low 1.31 on 5 Nov 2026. Last 15 sessions, 63.4% high to low

Profile

NXL
52-week range, 1% of the way up
1.3140.20

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices help people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

Employees8
IPOSep 16, 2022
Beta4.36
ATR, 14d0.34
Rel volume0.02
Short float1.40%
Insider own21.36%
Inst own9.03%

Snapshot

6 groups

Valuation

Index-
Market Cap1.76M
Enterprise Value0.76M
Income-8.99M
Sales0.22M
Book/sh2.07
Cash/sh0.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOSep 16, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S8.00
P/B0.74
P/C1.76
P/FCF-
EV/EBITDA-
EV/Sales3.45
Quick Ratio1.10
Current Ratio1.25
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-14.02
EPS next Y-7.55
EPS next Q-2.91
EPS this Y23.87%
EPS next Y33.89%
EPS next 5Y-
EPS past 3/5Y-29.12% -1.42%
Sales past 3/5Y-38.88% 4.43%
EPS Y/Y TTM32.15%
Sales Y/Y TTM24.22%
EPS Q/Q-5.30%
Sales Q/Q-82.77%
EarningsSep 02
EPS/Sales Surpr.-5.91% -86.44%

Ownership

Insider Own21.36%
Insider Trans0.00%
Inst Own9.03%
Inst Trans6.64%
ROA-187.89%
ROE-240.25%
ROIC-591.60%
Gross Margin-931.75%
Oper. Margin-4202.54%
Profit Margin-4139.38%
SMA20-13.57%
SMA50-56.40%
SMA200-85.00%
Trades-

Technical

Shs Outstand1.15M
Shs Float0.90M
Short Float1.40%
Short Ratio0.01
Short Interest0.01M
52W High40.20 -96.19%
52W Low1.31 16.79%
Volatility11.46% 12.82%
ATR (14)0.34
RSI (14)29.59
Beta4.36
Rel Volume0.02
Avg Volume1.02M
Volume4,489

Performance

Perf Week-1.92%
Perf Month-42.05%
Perf Quarter-85.45%
Perf Half Y-85.02%
Perf YTD-90.86%
Perf Year-95.89%
Perf 3Y-86.03%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price15.00
Prev Close1.47
Price1.53
Change %4.08%

Peers

Mkt cap
TickerCompanyMkt cap
ECORElectroCore Inc74.17M
STIMNeuronetics Inc125.99M
BWAYBrainsway Ltd ADR436.71M
MOBIMobia Medical Inc430.10M
NPCENeuroPace Inc436.43M
NMTCNeuroOne Medical Technologies Corp6.93M
LIVNLivaNova PLC4.99B
CLPTClearPoint Neuro Inc290.26M
VVOSVivos Therapeutics Inc2.98M
CMPSCompass Pathways Plc ADR1.32B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 204
  • Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease (GlobeNewswire)
  • Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing (GlobeNewswire)
  • Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization (InvestorsHub) +76.40%
  • Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation (GlobeNewswire)
  • Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy (GlobeNewswire)
  • Loading…
  • Nexalin Technology Announces Reverse Stock Split (GlobeNewswire) -13.63%
  • Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform (GlobeNewswire)
  • Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life (GlobeNewswire)
  • Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. (GlobeNewswire)
  • Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia (GlobeNewswire)
  • Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury (GlobeNewswire) +19.10%
  • Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial (GlobeNewswire)
  • Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia (GlobeNewswire) -8.62%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-3.177-3.000-3.1770.010.091
2026Q12026-06-03-3.300-3.300-3.1740.020.021
2025Q42026-02-25-3.900--3.9000.17--
2025Q22025-09-03-3.000-3.000-3.0170.070.071
2025Q12025-05-28-4.500-4.500-4.4830.040.041
2024Q42025-02-26-6.600-3.600-6.3890.030.031
2024Q32024-11-27-6.900--6.7710.040.03-
2025Q3---3.600-3.838-0.041
2026Q3---2.910--0.081
2026Q4---2.340--0.091
2027Q1---2.220--0.051
2027Q2---2.130--0.051
2027Q3---1.790--0.111
2027Q4---1.590--0.141

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-24.900-18.300-24.7640.170.17
2025FY-15.000--15.0000.30-
2026FY--11.420--0.19
2027FY--7.550--0.34

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-301010.080.080.08
2026Q3S2026-06-031000.090.090.09
2026Q3S2026-04-061000.090.090.09
2026Q3S2025-11-111000.180.180.18
2026Q3S2025-11-101000.180.180.18
2026Q3S2025-11-091000.180.180.18
2026Q3S2025-11-081000.180.180.18
2026Q3S2025-11-071000.180.180.18
2026Q3S2025-11-061000.180.180.18
2026Q3S2025-11-051000.180.180.18
2026Q3S2025-11-041000.180.180.18
2026Q3S2025-11-031000.180.180.18
2026Q3S2025-11-021000.180.180.18
2026Q3S2025-11-011000.180.180.18

Estimate history

EPS, annual-20.692-14.025-25.047-6.99-18.754-24.764-15.047-14.0175
Period2019202020212022202320242025TTM
EPS, quarterly-5.14-6.771-6.389-4.483-3.017-3.838-3.829-3.174-3.177
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.2070.2430.1441.3210.1110.1690.3020.22
Period2019202020212022202320242025TTM
Sales, quarterly0.0270.0360.0270.0410.0710.0180.1720.0150.012
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.2430.2430.2430.2430.2480.4430.640.733
Period2019202020212022202320242025MRQ
Shares, quarterly0.2530.4290.4430.4440.5810.6060.640.6860.733
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.220.300.170.111.320.140.240.21
Cost of Goods Sold Incl. D&A2.241.941.541.411.060.250.170.22
Gross Profit-2.02-1.64-1.37-1.300.26-0.110.08-0.01
Selling, General and Administrative Excl. Other7.106.756.394.392.105.913.331.46
Research and Development1.361.081.191.920.51---
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.13-8.39-7.75-5.70-1.83-6.02-3.26-1.47
Interest Expense---0.040.060.080.080.08
Unusual Expense0.000.000.00-0.61-0.02-0.020.073.47
Net Income Before Taxes-8.99-8.22-7.61-4.65-1.70-6.08-3.40-5.02
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.99-8.22-7.61-4.65-1.70-6.08-3.40-5.02
Net Income From Continuing Operations-8.99-8.22-7.61-4.65-1.70-6.08-3.40-5.02
Net Income-8.99-8.22-7.61-4.65-1.70-6.08-3.40-5.02
EPS (Recurring)-12.75-15.05-24.76-20.49-7.06-25.11-13.83-10.67
EPS (Basic, Before Extraordinaries)-14.02-15.05-24.76-18.75-6.99-25.05-14.03-20.69
EPS (Diluted)-14.02-15.05-24.76-18.75-6.99-25.05-14.03-20.69
EBITDA-9.08-8.37-7.74-5.69-1.83-6.02-3.26-1.47
Non-Operating Income (Expense)0.140.170.140.470.170.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.803.123.560.000.274.471.960.56
Price To Sales Ratio32.1330.32150.7527.184.13---
Gross Margin-931.75-543.35-810.78-1,176.4119.98-73.6631.30-5.22
Operating Margin-4,202.54-2,781.69-4,596.14-5,143.48-138.72-4,177.70-1,341.38-706.98
Net Margin-4,139.38-2,725.76-4,508.73-4,197.56-128.49-4,218.93-1,401.11-2,421.22
Shares Outstanding0.730.640.440.250.240.240.240.24
Market Capitalization1.691.6936.723.015.455.45--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.010.010.170.020.070.040.030.04
Cost of Goods Sold Incl. D&A0.530.510.750.450.390.350.580.31
Gross Profit-0.52-0.50-0.57-0.44-0.32-0.31-0.55-0.27
Selling, General and Administrative Excl. Other1.731.621.841.911.301.702.322.24
Research and Development0.560.350.220.230.230.410.740.18
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.25-2.12-2.41-2.35-1.62-2.01-2.88-2.51
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.24-2.10-2.38-2.28-1.58-1.99-2.83-2.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.24-2.10-2.38-2.28-1.58-1.99-2.83-2.45
Net Income From Continuing Operations-2.24-2.10-2.38-2.28-1.58-1.99-2.83-2.45
Net Income-2.24-2.10-2.38-2.28-1.58-1.99-2.83-2.45
EPS (Recurring)-3.18-3.17-3.83-3.84-3.02-4.48-6.39-6.77
EPS (Basic, Before Extraordinaries)-3.18-3.17-3.83-3.84-3.02-4.48-6.39-6.77
EPS (Diluted)-3.18-3.17-3.83-3.84-3.02-4.48-6.39-6.77
EBITDA-2.22-2.11-2.41-2.34-1.62-2.01-2.87-2.50
Non-Operating Income (Expense)0.010.020.040.070.040.020.040.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.410.480.831.080.570.641.551.54
Price To Sales Ratio32.1325.0534.45104.0088.82197.99217.6244.77
Gross Margin-4,242.11-3,319.53-334.26-2,405.75-457.09-750.70-2,032.21-751.68
Operating Margin-18,479.69-14,179.95-1,403.86-12,924.30-2,296.22-4,903.63-10,579.48-6,962.11
Net Margin-18,412.71-14,025.67-1,382.56-12,542.35-2,239.74-4,847.83-10,424.50-6,794.86
Shares Outstanding0.730.690.640.610.580.440.440.43
Market Capitalization1.697.1710.7116.6817.2125.9936.728.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments3.723.482.956.990.660.080.06
Short Term Receivables0.080.010.010.000.020.010.01
Inventories0.130.170.160.150.030.020.02
Other Current Assets0.360.290.320.270.040.010.02
Total Current Assets4.303.963.437.430.750.120.11
Net Property, Plant & Equipment0.000.000.000.010.000.000.00
Total Investments and Advances0.000.000.100.000.000.000.00
Intangible Assets0.340.260.110.000.000.000.00
Other Assets0.000.000.000.000.000.000.00
Total Assets4.644.223.637.430.750.120.11
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.750.780.600.59
Accounts Payable0.240.160.160.660.840.460.32
Other Current Liabilities0.640.390.260.540.740.510.13
Total Current Liabilities0.890.550.431.952.361.571.04
Long Term Debt0.000.000.000.000.070.140.25
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities0.890.550.431.952.441.711.29
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity3.753.683.215.48-1.68-1.59-1.18
Total Shareholders Equity3.753.683.215.48-1.68-1.59-1.18
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity3.753.683.215.48-1.68-1.59-1.18
Total Liabilities & Stockholders Equity4.644.223.637.430.750.120.11
Book Value Per Share5.868.2912.9422.56-6.93-6.55-4.86
Tangible Book Value Per Share5.337.7012.5122.56-6.93-6.55-4.86
Full-Time Employees8666-4-
Price to Book Ratio0.719.990.930.860.86--
Return on Assets-185.64-193.70-84.03-41.48-1,393.78-2,947.16-
Return on Equity-221.50-221.05-107.05-89.44---
Return on Invested Capital-219.38-206.94-144.97-30.96---
Quick Ratio4.706.937.703.730.310.060.09
Current Ratio4.857.258.073.810.320.070.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-8.99-8.22-7.61-4.65-1.70-6.08-3.40-5.02
Depreciation0.050.020.020.000.010.000.000.00
Other Funds (Non Cash)2.713.013.531.580.114.482.034.05
Funds from Operations-6.23-5.19-4.07-3.07-1.58-1.60-1.37-0.97
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.100.230.12-0.77-0.630.520.500.29
Cash from Operating Activities-6.13-4.96-3.94-3.84-2.22-1.08-0.86-0.68
Capital Expenditures-0.18-0.10-0.17-0.110.000.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments5.46-0.04-0.414.56-6.790.000.000.00
Purchase of Investments-25.66-40.76-33.63-36.72-6.790.000.000.00
Sale Or Maturity of Investments31.1240.7333.2241.280.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities5.28-0.13-0.584.45-6.790.00-0.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.525.174.520.008.551.470.950.66
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.525.174.520.008.551.470.950.66
Proceedsfrom Stock Options0.525.174.520.008.551.430.950.66
Issuance or Reduction of Debt, Net0.000.000.00-0.20-0.040.19-0.070.06
Change in Long Term Debt0.000.000.000.00-0.040.19-0.070.06
Issuance of Long Term Debt0.000.000.000.000.000.200.020.08
Reduction of Long Term Debt0.000.000.000.00-0.04-0.01-0.09-0.01
Net Financing Active Other Cash Flow0.890.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities1.425.174.52-0.208.511.660.880.73
Net Change in Cash0.570.08-0.010.42-0.500.580.020.05
Free Cash Flow-6.18-4.96-3.94-3.84-2.22-1.08-0.86-0.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.002.713.724.355.792.05
Short Term Receivables0.050.040.080.010.060.01
Inventories0.230.180.130.160.170.18
Other Current Assets0.570.360.360.300.240.38
Total Current Assets1.863.294.304.826.272.62
Net Property, Plant & Equipment0.040.050.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.100.360.340.310.290.28
Other Assets0.000.000.000.000.000.00
Total Assets3.003.694.645.136.562.90
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.240.170.240.070.240.18
Other Current Liabilities1.250.640.640.290.360.39
Total Current Liabilities1.480.810.890.360.600.57
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.480.810.890.360.600.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.522.893.754.775.962.33
Total Shareholders Equity1.522.893.754.775.962.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.522.893.754.775.962.33
Total Liabilities & Stockholders Equity3.003.694.645.136.562.90
Book Value Per Share2.074.215.867.8610.275.23
Tangible Book Value Per Share0.573.685.337.369.764.61
Full-Time Employees--8---
Price to Book Ratio0.712.482.863.502.8911.18
Return on Assets-187.89-252.65-185.64-167.17-217.81-298.36
Return on Equity-240.25-319.69-221.50-178.46-242.01-367.74
Return on Invested Capital-147.37-72.65-63.41-47.74-26.51-85.51
Quick Ratio1.103.854.7013.0310.154.25
Current Ratio1.254.074.8513.4710.444.56

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.24-2.10-2.38-2.28-1.58-1.99
Depreciation0.020.010.010.010.010.00
Other Funds (Non Cash)0.400.460.821.040.540.62
Funds from Operations-1.82-1.63-1.55-1.23-1.04-1.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.01-0.080.40-0.230.12-0.06
Cash from Operating Activities-1.80-1.71-1.15-1.47-0.92-1.43
Capital Expenditures-0.05-0.08-0.03-0.02-0.02-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments1.511.590.721.64-3.901.50
Purchase of Investments-1.00-4.00-8.76-11.90-15.10-5.00
Sale Or Maturity of Investments2.515.599.4813.5511.216.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.461.510.691.63-3.921.47
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.520.004.650.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.520.004.650.00
Proceedsfrom Stock Options0.000.000.520.004.650.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.140.760.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.140.760.520.004.650.00
Net Change in Cash-0.200.550.060.16-0.190.05
Free Cash Flow-1.80-1.76-1.15-1.47-0.92-1.43

Revenue breakdown

Device Sales2024: 55.50K 2025: 136.00K
Equipment2024: 37.83K 2025: 89.04K
Licensing Fee2024: 69.50K 2025: 49.11K
Other2024: 5.89K 2025: 27.49K
International2024: 85.25K 2025: 190.30K
United States2024: 83.47K 2025: 111.35K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.40%0.0M0.9M1.02M
2026-10-150.55%0.0M0.8M1.01M
2026-09-302.01%0.0M0.7M10.96K
2026-09-151.92%0.0M0.7M9.75K
2026-08-312.17%0.0M0.6M8.39K
2026-08-141.89%0.0M0.6M20.22K
2026-07-311.82%0.0M0.6M20.12K
2026-07-153.68%0.0M0.6M19.94K
2026-06-303.31%0.0M0.5M28.10K
2026-06-152.59%0.0M0.5M27.34K
2026-05-297.23%0.0M0.5M26.54K
2026-05-153.72%0.0M0.5M15.75K
2026-04-303.51%0.0M0.5M20.13K
2026-04-153.68%0.0M0.5M20.11K
2026-03-313.03%0.0M0.5M10.24K
2026-03-133.06%0.0M0.5M11.15K
2026-02-274.16%0.0M0.5M10.97K
2026-02-133.95%0.0M0.5M8.91K
2026-01-301.02%0.0M0.5M6.34K
2026-01-150.23%0.0M0.5M8.87K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-04SEC
2026-10-27PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-26SEC
2026-10-15EFFECTEffectiveness filing by commission orderSEC
2026-10-08S-1/ASEC
2026-10-018-KCurrent report2026-09-30SEC
2026-10-018-KCurrent report2026-09-28SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-22S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-03SCHEDULE 13DSEC
2026-09-03S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-028-KCurrent report2026-08-28SEC
2026-08-278-KCurrent report2026-08-26SEC
2026-08-27SCHEDULE 13GSEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-208-KCurrent report2026-08-19SEC
2026-08-20424B5SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-298-KCurrent report2026-07-28SEC
2026-07-278-KCurrent report2026-07-24SEC
2026-07-10ARSAnnual report to security holders. 2025-12-31SEC
2026-07-10DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-11SEC
2026-06-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-29SEC
2026-06-178-KCurrent report2026-06-16SEC
2026-05-198-KCurrent report2026-05-14SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-228-KCurrent report2026-04-17SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-258-KCurrent report2026-02-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
PEAK6 LLC1.17%
GEODE CAPITAL MANAGEMENT, LLC0.68%
VANGUARD CAPITAL MANAGEMENT LLC0.61%
UBS Group AG0.37%
CITADEL ADVISORS LLC0.37%
JANE STREET GROUP, LLC0.32%
VANGUARD FIDUCIARY TRUST CO0.25%
STATE STREET CORP0.16%
NORTHERN TRUST CORP0.12%
Kovack Advisors, Inc.0.11%

Funds

Fund% owned
Avantis International Small Cap Value ETF4.56%
Old Westbury Small & Mid Cap Strategies Fund0.72%
VANGUARD EXTENDED MARKET INDEX FUND0.61%
Avantis International Small Cap Value Fund0.32%
Avantis International Equity ETF0.15%
Avantis International Small Cap Equity ETF0.09%
Avantis Responsible International Equity ETF0.04%
Fidelity Nasdaq Composite Index Fund0.02%
Fidelity Extended Market Index Fund0.01%
Fidelity Total Market Index Fund0.00%

OakChart. NXL. Cached 15 minutes.

Some panels did not load: ratings, insider.